Literature DB >> 21815183

Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.

Amanda M Brandow1, Julie A Panepinto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21815183      PMCID： PMC3804029          DOI： 10.1002/ajh.22101

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  19 in total

1.  Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation.

Authors:  Stephanie J Lee; Steven Joffe; Haesook T Kim; Gerard Socie; Andrew L Gilman; John R Wingard; Mary M Horowitz; David Cella; Karen L Syrjala
Journal:  Blood       Date:  2004-06-15       Impact factor: 22.113

2.  Transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists.

Authors:  Edward C C Wong; Evelio Perez-Albuerne; Jeffrey A Moscow; Naomi L C Luban
Journal:  Pediatr Blood Cancer       Date:  2005-02       Impact factor: 3.167

Review 3.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

4.  Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.

Authors:  Mariane de Montalembert; Valentine Brousse; Caroline Elie; Françoise Bernaudin; Junxin Shi; Paul Landais
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

5.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Authors:  Martin H Steinberg; Franca Barton; Oswaldo Castro; Charles H Pegelow; Samir K Ballas; Abdullah Kutlar; Eugene Orringer; Rita Bellevue; Nancy Olivieri; James Eckman; Mala Varma; Gloria Ramirez; Brian Adler; Wally Smith; Timothy Carlos; Kenneth Ataga; Laura DeCastro; Carolyn Bigelow; Yogen Saunthararajah; Margaret Telfer; Elliott Vichinsky; Susan Claster; Susan Shurin; Kenneth Bridges; Myron Waclawiw; Duane Bonds; Michael Terrin
Journal:  JAMA       Date:  2003-04-02       Impact factor: 56.272

6.  Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists.

Authors:  Marc S Zumberg; Suresh Reddy; Robert L Boyette; Robert J Schwartz; Thomas R Konrad; Richard Lottenberg
Journal:  Am J Hematol       Date:  2005-06       Impact factor: 10.047

7.  The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns.

Authors:  Michael B Streiff; Brad Smith; Jerry L Spivak
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial.

Authors:  A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

9.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Authors:  Sherri A Zimmerman; William H Schultz; Jacqueline S Davis; Chrisley V Pickens; Nicole A Mortier; Thad A Howard; Russell E Ware
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113
View more
  13 in total

1.  Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia.

Authors:  Winfred C Wang; Suzette O Oyeku; Zhaoyu Luo; Sheree L Boulet; Scott T Miller; James F Casella; Billie Fish; Bruce W Thompson; Scott D Grosse
Journal:  Pediatrics       Date:  2013-09-02       Impact factor: 7.124

2.  The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Authors:  Shuaiying Cui; Kim-Chew Lim; Lihong Shi; Mary Lee; Natee Jearawiriyapaisarn; Greggory Myers; Andrew Campbell; David Harro; Shigeki Iwase; Raymond C Trievel; Angela Rivers; Joseph DeSimone; Donald Lavelle; Yogen Saunthararajah; James Douglas Engel
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  Greater number of perceived barriers to hydroxyurea associated with poorer health-related quality of life in youth with sickle cell disease.

Authors:  Arlene Smaldone; Deepa Manwani; Nancy S Green
Journal:  Pediatr Blood Cancer       Date:  2019-04-02       Impact factor: 3.167

4.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

5.  Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.

Authors:  Arlene Smaldone; Sally Findley; Suzanne Bakken; L Adriana Matiz; Susan L Rosenthal; Haomiao Jia; Sergio Matos; Deepa Manwani; Nancy S Green
Journal:  Contemp Clin Trials       Date:  2016-06-17       Impact factor: 2.226

Review 6.  Medication adherence among pediatric patients with sickle cell disease: a systematic review.

Authors:  Kathleen E Walsh; Sarah L Cutrona; Patricia L Kavanagh; Lori E Crosby; Chris Malone; Katie Lobner; David G Bundy
Journal:  Pediatrics       Date:  2014-11-17       Impact factor: 7.124

7.  Hydroxyurea use among children with sickle cell anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Pediatr Blood Cancer       Date:  2019-03-22       Impact factor: 3.167

Review 8.  Travelers with sickle cell disease.

Authors:  Shaina M Willen; Courtney D Thornburg; Paul M Lantos
Journal:  J Travel Med       Date:  2014-06-19       Impact factor: 8.490

9.  Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.

Authors:  Nicole M Alberts; Sherif M Badawy; Jerlym S Porter; Jane S Hankins; Jason Hodges; Jeremie H Estepp; Chinonyelum Nwosu; Hamda Khan; Matthew P Smeltzer; Ramin Homayouni; Sarah Norell; Lisa Klesges
Journal:  JMIR Mhealth Uhealth       Date:  2020-05-08       Impact factor: 4.773

10.  Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.

Authors:  Sherif M Badawy; Alexis A Thompson; Jin-Shei Lai; Frank J Penedo; Karen Rychlik; Robert I Liem
Journal:  Health Qual Life Outcomes       Date:  2017-07-05       Impact factor: 3.186
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.